Cochrane · systematic review · CD011300
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non‐small cell lung cancer treated with surgery or radiotherapy with curative intent
Zhu, J, Yuan, Y, Wan, X, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 37.5%Moderate 4 · 50%High 1 · 12.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyImmunotherapy for surgically‐treated patients with non‐small cell lung cancer (NSCLC), with or without radiotherapy with curative intent
Population: stages I to III NSCLC patients treated with surgery or radiotherapy with curative intent
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (Duration of | HR 0.94 [0.84, 1.05] | 4 studies · 3848 participants | High |
Progression‐free survival | HR 0.94 [0.86, 1.03] | 5 studies · 3861 participants | Moderate Downgraded: risk of bias |
Overall survival: 1‐year survival rate  | RR 1.02 [0.96, 1.08] | 7 studies · 4420 participants | Low Downgraded: risk of bias, inconsistency |
Overall survival: 2‐year survival rate | RR 1.02 [0.93, 1.12] | 7 studies · 4420 participants | Moderate Downgraded: risk of bias |
Overall survival: 3‐year survival rate | RR 0.99 [0.9, 1.09] | 7 studies · 4420 participants | Moderate Downgraded: risk of bias |
Overall survival: 5‐year survival rate | RR 0.98 [0.86, 1.12] | 7 studies · 4389 participants | Moderate Downgraded: risk of bias |
Adverse events: any (Duration of | RR 1.12 [0.97, 1.28] | 4 studies · 4126 participants | Low Downgraded: risk of bias, inconsistency |
Adverse events: severe, grade > 2 (Duration of | RR 1.14 [0.92, 1.4] | 6 studies · 4546 participants | Low Downgraded: risk of bias, inconsistency |
Immunotherapy for surgically‐treated patients with NSCLC, with or without radiotherapy with curative intent
Population: stages I to III non‐small cell lung cancer (NSCLC) treated with surgery or radiotherapy with curative intent
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Duration of | HR 0.94 [0.83, 1.06] | 3 studies · 3693 participants | High |
Progression‐free survival | HR 0.93 [0.81, 1.07] | 3 studies · 3693 participants | High |
Overall survival, 1‐year survival rate | RR 1.01 [0.95, 1.08] | 6 studies · 4265 participants | Low Downgraded: inconsistency |
Overall survival, 3‐year survival rate | RR 1 [0.89, 1.12] | 6 studies · 4265 participants | Moderate Downgraded: risk of bias, inconsistency |
Overall survival, 5‐year survival rate | RR 0.98 [0.86, 1.12] | 6 studies · 4234 participants | Moderate Downgraded: risk of bias, inconsistency |
Adverse event (any) Duration of | RR 1.15 [0.97, 1.37] | 3 studies · 3955 participants | Moderate Downgraded: inconsistency |
Adverse event (severe, grade > 2) Duration of | RR 1.1 [0.88, 1.39] | 4 studies · 4362 participants | Low Downgraded: inconsistency |